Sphingomonas Extract Modulates Immune Response and Skin Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cutaneous reactions caused by allergic reactions are inadequate in effectively modulating the immune response and reinforcing the skin's barrier function, as they often fail to address the underlying inflammatory mechanisms and IgE production.
Innovation Solution
An extract of Sphingomonas bacteria is used to activate hTLR2 receptors, promote the expression of genes related to skin barrier reinforcement, inhibit pro-inflammatory mediator PGE2 secretion, and modulate interleukin expressions to increase IL-10 production, while limiting IgE production by human B lymphocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cutaneous reactions, then some symptomatic relief may be achieved, but the underlying inflammatory mechanisms and immune response are not effectively modulated
Solution Approach 1:
The patent utilizes the bacterial extract from Sphingomonas species, which naturally produces compounds that can be converted into therapeutic benefits. The extract contains metabolites that selectively modulate immune responses, transforming a potential pathogen into a beneficial treatment for allergic cutaneous reactions by activating TLR2 receptors and promoting anti-inflammatory cytokine production
Solution Approach 2:
The invention changes the chemical and biological parameters of the treatment by using a complex mixture of bacterial metabolites rather than single synthetic compounds. This parameter change allows for multi-target modulation of the immune system, affecting multiple inflammatory pathways simultaneously while maintaining selective anti-inflammatory activity
2Reliability
If the immune response is strongly activated to fight allergens, then protective immunity is enhanced, but pro-inflammatory mediators and IgE production increase causing allergic reactions
Solution Approach 1:
Instead of using strong immunosuppressants that broadly inhibit immune responses, the patent inverts the approach by using bacterial extracts that selectively promote anti-inflammatory pathways while maintaining protective immunity. The Sphingomonas extract activates TLR2 receptors to induce IL-10 production, creating a targeted anti-inflammatory effect that does not compromise overall immune protection
Solution Approach 2:
The bacterial extract acts as an intermediary substance that mediates between the immune system and allergens. It contains specific metabolites that interact with TLR2 receptors on immune cells, triggering a cascade of anti-inflammatory cytokine production that bridges the gap between maintaining immune surveillance and preventing allergic inflammation
3Reliability
If the skin barrier function is reinforced to prevent allergen penetration, then allergic reactions are reduced, but the treatment complexity increases
Solution Approach 1:
The Sphingomonas bacterial extract exhibits multi-functionality by simultaneously reinforcing skin barrier function and modulating immune responses. The same extract that activates TLR2 receptors to promote anti-inflammatory cytokines also stimulates keratinocyte differentiation and tight junction formation, providing dual benefits in a single treatment formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Sphingomonas extract demonstrates anti-inflammatory activities and enhances skin barrier function, effectively preventing and treating cutaneous reactions by reducing inflammation and immune response activity.
Implementation Method 1
By stimulating the expression of these proteins and the formation of the tight junctions, the activation of the Toll 2 (TLR2) type receptors allows reinforcing the barrier function
Implementation Method 2
They have also shown that this extract allows inhibiting the secretion of the pro-inflammatory mediator PGE2
Implementation Method 3
modulating the expressions of interleukins promoting IL-10 (anti-inflammatory cytokine)
Implementation Method 4
Finally, the inventors have shown that the extract allowed limiting the IgE production by human B lymphocytes
Data Source
AI summary
The present invention relates to an extract of bacteria of the genus Sphingomonas, and compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for use in the prevention and/or the treatment of cutaneous reactions caused by an allergic reaction and for use in the modulation of the immune response and optionally in the reinforcement of the barrier function of the skin.